Korea's Hanwha Chemical Leads With Enbrel Biosimilar - BIO Korea
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Hanwha Chemical Corp. - a latecomer to the biopharma industry - is trying to carve out a share of the biosimilars market with a version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept), which is to be sold by Merck & Co. outside of Korea
You may also be interested in...
Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
Dong-A Pharmaceutical, Meiji Seika Pharma Join For Biosimilar Distribution In Japan And Korea
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul